2 assets in Gastric Neuroendocrine Tumor G1

Therapeutic assets addressing Gastric Neuroendocrine Tumor G1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Gastric Neuroendocrine Tumor G1	National Cancer Institute (NCI)	P3	B (60)
Interferon Alfa-2B Gastric Neuroendocrine Tumor G1	National Cancer Institute (NCI)	P3	B (59)